Immutep Ltd ADR Dividends
The next dividend date for Immutep Ltd ADR has not yet been scheduled.
What is a Dividend Date
When we talk about a dividend date, we’re referring specifically to the ex-dividend date.
This is the date on which all stockholders will earn a dividend. Technically, a person needs to be the owner of a share of stock as of the night before the ex-dividend date in order to earn the dividend.
The ex-dividend date is different than the date when the dividend is issued. Although you earn a dividend on the ex-dividend date, that dividend is typically not disbursed to your account until several weeks later.
Most brokerages will automatically credit the dividend to your account once it’s issued.
Historical Dividends for Immutep Ltd ADR (IMMP)
More About Immutep Ltd ADR
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Owning Immutep Ltd ADR Stock on the Dividend Date
If you own Immutep Ltd ADR stock on the ex-dividend date, then you earn the associated dividend.
Theoretically, the price of Immutep Ltd ADR stock should go down by the amount of the dividend (in addition to any other pressures that market forces have on the price of Immutep Ltd ADR stock).
Therefore, it is typically not expected that there is any incremental profit to be gained from buying Immutep Ltd ADR stock right before the ex-dividend date and then selling it immediately after. It’s not like you get the Immutep Ltd ADR dividend payout for free just by doing that since there is typically an equivalent commensurate drop in the stock price.
Learning More Immutep Ltd ADR Dividends
You can contact us any time if you would like to ask questions about Immutep Ltd ADR dividends or anything else related to the stock market.